Cancer Research and Biotechnology AG is a Swiss preclinical oncology company focusing on metabolic diseases and mitochondrial healing for cancer treatments.
CRB is developing new-generation cancer treatments that selectively eradicate cancer cells without inducing toxicity.
FIRST-IN-CLASS ONCOLOGY DRUG
The physiological and psychological damages caused by conventional treatments are a burden on patients and require a long journey towards remission.
CRB reduces these burdens by using non-toxic small molecules that restore the balance in metabolic cellular pathways. The result is a powerful combination of efficacy and safety, a need that is rare and highly unmet in cancer care today.
TARGETING DEADLY CANCERS
The first target is Triple Negative Breast Cancer, a very aggressive form of breast cancer.
Our drug has shown efficacy and safety on human cancer cells, and it will soon be studied in clinical trials.
